Medication info

Bacrlax Injection 250mg (Acyclovir)

Prescription medicationExpired
Ingredient · strength
Acyclovir›Strength being verified
Manufacturer / importer
Aprogen Biologics Co., Ltd.
Appearance
It is an injection solution filled with a nearly transparent liquid.
Packaging
1 vial (10 milliliters) × 1, 3, 5, 10, 20, 30, 50, 100
Approval status
Expired

MFDS item code 199800322 · Notified 1998.04.06

This product's status changed to Expired on 2023.04.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment and prevention of herpes simplex (e.g., genital herpes and encephalitis); treatment of chickenpox and shingles
Who uses it
Adults · Children
Adult dosage
○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg 5 times daily at 4-hour intervals for 5 days. In severe initial infections, treatment may be extended. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) It is best to start treatment as soon as possible after infection. In recurrent infections, treatment should preferably be started at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer 200 mg of this drug 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg may be administered twice daily at 12-hour intervals. 2) The dose may then be reduced to 200 mg 2~3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, long-term treatment should be periodically interrupted every 6~12 months for evaluation. 3. Prevention of herpes simplex infections in immunocompromised patients 1) Administer 200 mg of this drug 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer 800 mg of this drug 5 times daily at approximately 4-hour intervals, excluding bedtime, for a total of 7 days. 2) Intravenous administration should be considered in patients with severe immunodeficiency or gastrointestinal malabsorption. 3) It is best to start treatment as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more likely to experience neuropsychiatric adverse reactions; therefore, caution should be taken, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL/min), it is preferable to administer 200 mg of this drug every 12 hours. 2. Treatment of herpes zoster virus infections In patients with severe renal impairment (creatinine clearance less than 10 mL/min), it is preferable to reduce the dose to 800 mg of this drug 3~4 times daily at approximately 6~8-hour intervals. (Injection) For each administration, the injection should be given by slow intravenous infusion over at least 1 hour. A treatment duration of 5 days is appropriate, but may be adjusted according to the patient's symptoms and healing status. Herpes simplex encephalitis is usually treated for 10 days. 1. Adults 1) Herpes simplex infections: In patients with normal or impaired immune function, administer acyclovir 5 mg/kg body weight every 8 hours. 2) Recurrent varicella-zoster virus infections: In patients with normal immune function, administer 5 mg/kg body weight of this drug every 8 hours. 3) Initial and recurrent varicella-zoster virus infections: In immunocompromised patients, administer 10 mg/kg body weight of this drug every 8 hours. 4) Herpes simplex encephalitis: In patients with normal or impaired immune function, administer 10 mg/kg body weight of this drug every 8 hours. 5) Prevention of herpes simplex virus infections in immunocompromised patients: Consider when oral administration is not possible; determine the duration of treatment according to the period of risk of infection. 2. Patients with renal impairment are more likely to experience neuropsychiatric adverse reactions; use with caution. The dosage is as follows. Creatinine clearance (mL/min) 25~50 Administer the recommended dose for the above indication every 12 hours 10~25 Administer the recommended dose for the above indication every 24 hours 0 (anuria)~10 For patients receiving peritoneal dialysis, administer half the recommended dose (2.5 or 5 mg/kg body weight) every 24 hours. For patients receiving hemodialysis, administer half the recommended dose (2.5 or 5 mg/kg body weight) every 24 hours and after dialysis. 4. Preparation of solution Dissolve 1 vial (containing 250 mg of acyclovir) by adding 10 mL of Water for Injection or 0.9%w/v saline injection for intravenous use. Then administer by intravenous injection using an infusion pump that allows the infusion volume to be adjusted, or dilute and administer by intravenous infusion. 5. Method of administration 1) For intravenous injection using an infusion pump, administer the acyclovir 25 mg/mL solution as is over at least 1 hour. 2) For intravenous infusion after dilution, the acyclovir concentration must be 0.5%w/v or less. Dilute a vial containing 250 mg in at least 50 mL of solution and administer over at least 1 hour. 3) For dilution in this case, the following infusion solutions may be used; the solution is stable for 12 hours at room temperature (15~25℃). (1) 0.45%w/v or 0.9%w/v saline injection for intravenous infusion (2) A mixture of 0.18%w/v saline injection and 4%w/v glucose for intravenous infusion (3) A mixture of 0.45%w/v saline injection and 2.5%w/v glucose for intravenous infusion (4) Compound sodium lactate solution for intravenous infusion (Hartmann's solution) 4) After adding this drug to the infusion solution, shake the mixture thoroughly to ensure it is fully mixed. 5) If cloudiness or crystals are visible in the solution before or during infusion, discard the mixture. Do not refrigerate the solution.
Children's dosage
○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in patients with impaired immune function 1) 2 years and older: Same as the adult dose. 2) Under 2 years: Administer 1/2 the adult dose. 3) There are no conclusive data yet on prevention of herpes simplex virus infections in patients with normal immune function. 2. Treatment of chickenpox in children 2 years and older: Administer 20 mg/kg body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. Treatment should be started as soon as possible after the chickenpox rash appears, preferably within 24 hours of rash onset. 3. Children The dose for children (3 months~12 years) is calculated according to body surface area and administered according to the adult regimen. 1) Herpes simplex (excluding herpes simplex encephalitis) or varicella-zoster virus infection: Administer 250 mg per ㎡ of body surface area every 8 hours. 2) Children with impaired immune function infected with varicella-zoster virus or with herpes simplex encephalitis: If renal function is normal, administer 500 mg per ㎡ of body surface area every 8 hours. For pediatric patients with renal impairment, adjust the dose appropriately according to the degree of impairment.

Ingredients

Manufacturer
Aprogen Biologics Co., Ltd.

Efficacy & effects

Treatment and prevention of herpes simplex (e.g., genital herpes and encephalitis); treatment of chickenpox and shingles

  • Genital herpes
  • herpes simplex virus infections of the skin and mucous tissue
  • herpes zoster viral infections
  • acute pain
  • chickenpox
  • severe primary genital herpes
  • recurrent herpes zoster viral infections
  • herpes simplex encephalitis
  • herpes simplex virus infections
  • primary and recurrent herpes zoster viral infections
View approved original text

This medication is used for the treatment and prevention of herpes simplex virus infections in the skin and mucous membranes, including primary and recurrent genital herpes. It is also effective in treating herpes zoster viral infection, especially helping to relieve acute pain. It is used for the treatment of chickenpox in children aged 2 years and older. The injection is used to treat severe primary genital herpes, recurrent herpes zoster virus infections, and herpes simplex encephalitis in patients with normal immune function; in immunocompromised patients, it is utilized for the treatment and prevention of herpes simplex virus infections, primary and recurrent herpes zoster virus infections, and herpes simplex encephalitis. This medication effectively treats virus-related diseases and improves symptoms.

Dosage and Administration

Adult dosage

○ Adults 1. Treatment of herpes simplex virus infections 1) Administer acyclovir 200 mg 5 times daily at 4-hour intervals for 5 days. In severe initial infections, treatment may be extended. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) It is best to start treatment as soon as possible after infection. In recurrent infections, treatment should preferably be started at the first sign of prodromal symptoms or lesions. 2. Prevention of herpes simplex infections in patients with normal immune function 1) Administer 200 mg of this drug 4 times daily at approximately 6-hour intervals. Alternatively, 400 mg may be administered twice daily at 12-hour intervals. 2) The dose may then be reduced to 200 mg 2~3 times daily after confirming its efficacy. 3) To assess the natural course of the disease, long-term treatment should be periodically interrupted every 6~12 months for evaluation. 3. Prevention of herpes simplex infections in immunocompromised patients 1) Administer 200 mg of this drug 4 times daily at approximately 6-hour intervals. 2) In patients with severe immunodeficiency (e.g., after bone marrow transplantation) or gastrointestinal malabsorption, the dose may be increased to 400 mg per administration or the route of administration may be changed to intravenous injection. 3) Administer during the period of risk of infection. 4. Treatment of herpes zoster infections 1) Administer 800 mg of this drug 5 times daily at approximately 4-hour intervals, excluding bedtime, for a total of 7 days. 2) Intravenous administration should be considered in patients with severe immunodeficiency or gastrointestinal malabsorption. 3) It is best to start treatment as soon as possible after infection; the earlier treatment is started, the better the effect. ○ Patients with renal impairment Patients with renal impairment are more likely to experience neuropsychiatric adverse reactions; therefore, caution should be taken, including by extending the dosing interval or reducing the dose. 1. Treatment of herpes simplex infections The oral dose is generally not higher than the amount that would accumulate with intravenous administration. However, in patients with severe renal impairment (creatinine clearance less than 10 mL/min), it is preferable to administer 200 mg of this drug every 12 hours. 2. Treatment of herpes zoster virus infections In patients with severe renal impairment (creatinine clearance less than 10 mL/min), it is preferable to reduce the dose to 800 mg of this drug 3~4 times daily at approximately 6~8-hour intervals. (Injection) For each administration, the injection should be given by slow intravenous infusion over at least 1 hour. A treatment duration of 5 days is appropriate, but may be adjusted according to the patient's symptoms and healing status. Herpes simplex encephalitis is usually treated for 10 days. 1. Adults 1) Herpes simplex infections: In patients with normal or impaired immune function, administer acyclovir 5 mg/kg body weight every 8 hours. 2) Recurrent varicella-zoster virus infections: In patients with normal immune function, administer 5 mg/kg body weight of this drug every 8 hours. 3) Initial and recurrent varicella-zoster virus infections: In immunocompromised patients, administer 10 mg/kg body weight of this drug every 8 hours. 4) Herpes simplex encephalitis: In patients with normal or impaired immune function, administer 10 mg/kg body weight of this drug every 8 hours. 5) Prevention of herpes simplex virus infections in immunocompromised patients: Consider when oral administration is not possible; determine the duration of treatment according to the period of risk of infection. 2. Patients with renal impairment are more likely to experience neuropsychiatric adverse reactions; use with caution. The dosage is as follows. Creatinine clearance (mL/min) 25~50 Administer the recommended dose for the above indication every 12 hours 10~25 Administer the recommended dose for the above indication every 24 hours 0 (anuria)~10 For patients receiving peritoneal dialysis, administer half the recommended dose (2.5 or 5 mg/kg body weight) every 24 hours. For patients receiving hemodialysis, administer half the recommended dose (2.5 or 5 mg/kg body weight) every 24 hours and after dialysis. 4. Preparation of solution Dissolve 1 vial (containing 250 mg of acyclovir) by adding 10 mL of Water for Injection or 0.9%w/v saline injection for intravenous use. Then administer by intravenous injection using an infusion pump that allows the infusion volume to be adjusted, or dilute and administer by intravenous infusion. 5. Method of administration 1) For intravenous injection using an infusion pump, administer the acyclovir 25 mg/mL solution as is over at least 1 hour. 2) For intravenous infusion after dilution, the acyclovir concentration must be 0.5%w/v or less. Dilute a vial containing 250 mg in at least 50 mL of solution and administer over at least 1 hour. 3) For dilution in this case, the following infusion solutions may be used; the solution is stable for 12 hours at room temperature (15~25℃). (1) 0.45%w/v or 0.9%w/v saline injection for intravenous infusion (2) A mixture of 0.18%w/v saline injection and 4%w/v glucose for intravenous infusion (3) A mixture of 0.45%w/v saline injection and 2.5%w/v glucose for intravenous infusion (4) Compound sodium lactate solution for intravenous infusion (Hartmann's solution) 4) After adding this drug to the infusion solution, shake the mixture thoroughly to ensure it is fully mixed. 5) If cloudiness or crystals are visible in the solution before or during infusion, discard the mixture. Do not refrigerate the solution.

Children's dosage

○ Children 1. Treatment of herpes simplex infections and prevention of herpes simplex infections in patients with impaired immune function 1) 2 years and older: Same as the adult dose. 2) Under 2 years: Administer 1/2 the adult dose. 3) There are no conclusive data yet on prevention of herpes simplex virus infections in patients with normal immune function. 2. Treatment of chickenpox in children 2 years and older: Administer 20 mg/kg body weight per dose (maximum 800 mg per dose) 4 times daily for 5 days. Treatment should be started as soon as possible after the chickenpox rash appears, preferably within 24 hours of rash onset. 3. Children The dose for children (3 months~12 years) is calculated according to body surface area and administered according to the adult regimen. 1) Herpes simplex (excluding herpes simplex encephalitis) or varicella-zoster virus infection: Administer 250 mg per ㎡ of body surface area every 8 hours. 2) Children with impaired immune function infected with varicella-zoster virus or with herpes simplex encephalitis: If renal function is normal, administer 500 mg per ㎡ of body surface area every 8 hours. For pediatric patients with renal impairment, adjust the dose appropriately according to the degree of impairment.

Precautions

This medication should not be used in patients who are allergic to this medication or its components. In patients with poor kidney function, this medication should be used with caution, and monitoring is needed as central nervous system symptoms may occur. It should also be administered cautiously to patients with impaired liver function, as the risk of worsening liver function may increase. In infants and children, it should be used minimally and only when necessary, especially in neonates or premature infants where safety has not been established, caution is required. Elderly patients are likely to have reduced kidney function, which may increase the concentration of this medication, therefore, careful administration with adjusted dosage and intervals is necessary. Serious allergic reactions such as anaphylactic shock may rarely occur when this medication is used; if symptoms such as low blood pressure, difficulty breathing, or chest tightness occur, administration should be stopped immediately, and appropriate treatment should be sought. Skin reactions such as rash, fever, blisters, or urticaria may occur, so if these symptoms appear, administration should be discontinued. Rarely, hair loss, severe skin diseases, neurological symptoms (e.g., confusion, hallucinations, seizures), kidney issues, liver function abnormalities, gastrointestinal symptoms (gastritis, nausea, vomiting, etc.), blood abnormalities, and cardiovascular issues may occur, and if any abnormal symptoms arise, report to medical personnel immediately. It is most effective to administer this medication as early as possible after disease onset, particularly starting as soon as possible after symptoms of herpes zoster or chickenpox appear. During administration, it is important to maintain adequate hydration to prevent dehydration and reduce the risk of kidney toxicity. Interactions may occur when used with other medications, so inform medical personnel of any current medications you are taking. Women who are pregnant or may become pregnant should only use this medication if the benefits outweigh the risks to the fetus. This medication is also excreted in breast milk, so it is recommended to discontinue breastfeeding during treatment. In case of overdose, kidney damage may occur, and central nervous system symptoms (agitation, stupor, seizures, etc.) may arise, so seek appropriate medical treatment immediately. When administering by injection, it should be given slowly via a drip infusion rather than rapid intravenous injection, and care should be taken to prevent pain or inflammation at the injection site. This medication is alkaline, so it is advisable to avoid mixing it with other medications for injection.

Side effects

  • Anaphylactic shock
  • anaphylactic reaction
  • hypotension
  • dyspnea
  • chest tightness
  • photosensitivity reaction
  • fixed drug eruption
  • rash
  • fever
  • vesicles
Show 128 more
  • urticaria-like erythema
  • urticaria
  • alopecia
  • erythema multiforme
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • altered consciousness
  • disorientation
  • concentration disorder
  • aggressive behavior
  • depersonalization
  • anxiety
  • ataxia
  • coma
  • confusion
  • delirium
  • stuttering
  • encephalopathy
  • hallucinations
  • psychosis
  • seizures
  • drowsiness
  • tremors
  • agitation
  • forgetfulness
  • insomnia
  • anxiety
  • soliloquy
  • abnormal sensations
  • ataxia
  • inability to walk
  • involuntary movements
  • nystagmus
  • renal failure
  • crystalluria
  • elevated BUN
  • elevated serum creatinine
  • hematuria
  • proteinuria
  • urinary red blood cell casts
  • pyuria
  • leukocytoclastic vasculitis
  • lymphadenopathy
  • bleeding
  • purpura
  • anemia
  • leukopenia
  • leukocytosis
  • eosinophilia
  • lymphocytosis
  • thrombocytosis
  • granulocytopenia
  • thrombocytopenia
  • basophilia
  • hepatitis
  • liver dysfunction
  • jaundice
  • abnormal liver function tests
  • hepatomegaly
  • gastritis
  • thirst
  • constipation
  • acute pancreatitis
  • diarrhea
  • soft stools
  • upper abdominal pain
  • gastric pain
  • abdominal pain
  • nausea
  • vomiting
  • indigestion
  • loss of appetite
  • glossitis
  • fever
  • peripheral edema
  • syncope
  • pallor
  • muscle weakness
  • lethargy
  • generalized malaise
  • headache
  • arthralgia
  • myalgia
  • arrhythmia
  • chest pain
  • hypertension
  • hypotension
  • tachycardia
  • palpitations
  • urinary obstruction
  • dysuria
  • glucosuria
  • pneumonia
  • pharyngitis
  • pleural effusion
  • pain
  • hearing loss
  • conjunctivitis
  • visual disturbances
  • taste disorders
  • sweating
  • hyponatremia
  • hypoproteinemia
  • increased total cholesterol
  • increased triglycerides
  • elevated serum potassium
  • decreased serum albumin
  • nonsense speech
  • speech disorder
  • paresthesia in the lower limbs
  • numbness of the tongue and limbs
  • somnolence
  • generalized malaise
  • bipolar disorder
  • emotional instability
  • concentration disorder
  • forgetfulness
  • ataxia
  • soliloquy
  • gait abnormality
  • involuntary movements
  • dysuria
  • edema
  • cold sensitivity
  • chest discomfort
  • ulcer
  • vascular pain
  • vascular weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent exposure to air and kept in a cool place below 25 degrees. This preserves the effectiveness of the medication and prevents deterioration.

Appearance and packaging

Appearance

It is an injection solution filled with a nearly transparent liquid.

Package unit

1 vial (10 milliliters) × 1, 3, 5, 10, 20, 30, 50, 100

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.